Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurol Neurosurg Psychiatry ; 77(1): 18-23, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16361586

ABSTRACT

BACKGROUND: Segawa syndrome due to GTP cyclohydrolase deficiency is an autosomal dominant disorder with variable expression, that is clinically characterised by l-dopa responsive, diurnally fluctuating dystonia and parkinsonian symptoms. OBJECTIVE: To delineate the neurological and psychiatric phenotype in all affected individuals of three extended families. METHODS: GTP cyclohydrolase deficiency was documented by biochemical analyses, enzymatic measurements in fibroblasts, and molecular investigations. All affected individuals were examined neurologically, and psychiatric data were systematically reviewed. RESULTS: Eighteen affected patients from three families with proven GTP cyclohydrolase deficiency were identified. Eight patients presenting at less than 20 years of age had typical motor symptoms of dystonia with diurnal variation. Five family members had late-presenting mild dopa-responsive symptoms of rigidity, frequent falls, and tendonitis. Among mutation carriers older than 20 years of age, major depressive disorder, often recurrent, and obsessive-compulsive disorder were strikingly more frequent than observed in the general population. Patients responded well to medication increasing serotonergic neurotransmission and to l-dopa substitution. Sleep disorders including difficulty in sleep onset and maintenance, excessive sleepiness, and frequent disturbing nightmares were present in 55% of patients. CONCLUSION: Physicians should be aware of this expanded phenotype in affected members of families with GTP cyclohydrolase deficiency.


Subject(s)
Dystonia/enzymology , Dystonia/genetics , GTP Cyclohydrolase/deficiency , GTP Cyclohydrolase/genetics , Paraparesis, Spastic/genetics , Parkinsonian Disorders/genetics , Tremor/genetics , Adolescent , Adult , Circadian Rhythm/physiology , Dystonia/complications , Female , Fibroblasts/enzymology , Gene Expression , Humans , Lower Extremity/physiopathology , Male , Middle Aged , Paraparesis, Spastic/complications , Parkinsonian Disorders/complications , Pedigree , Phenotype , Phenylalanine/blood , Polymerase Chain Reaction , Reflex, Abnormal , Syndrome , Tendinopathy/complications , Tremor/complications
2.
J Inherit Metab Dis ; 28(5): 651-63, 2005.
Article in English | MEDLINE | ID: mdl-16151895

ABSTRACT

High-dose benzoate treatment aimed at reducing plasma glycine levels to normal reduces seizures and increases wakefulness in patients with nonketotic hyperglycinaemia (NKH). Since benzoate metabolism is dependent on the available glycine pool, and since the glycine pool is variably affected by the deficiency in the glycine cleavage enzyme system, we examined the importance of interpatient variability in benzoate requirement. To correct for the dietary glycine contribution, the glycine index was introduced as the molar requirement of benzoate dose necessary to normalize plasma glycine levels and subtracting from that the dietary glycine intake, both corrected for weight. The glycine index varied between 3.62 and 4.87 mmol/kg per day in five patients with a poor neurodevelopmental outcome and between 0.92 and 1.90 mmol/kg per day in four patients with a better neurodevelopmental outcome, and was 2.54 mmol/kg per day in a single patient with an intermediate outcome. The glycine index was stable over time within each patient. Exceeding the balance by either increasing food glycine intake or decreasing the benzoate dose resulted in increased glycine levels. Exceeding the glycine tolerance by increasing benzoate resulted in elevated and toxic levels of benzoate. The glycine index is a stable, individually specific parameter in patients with NKH. It has clinical consequences for the dose of benzoate required and the role of dietary management. Through its correlation with neurodevelopmental outcome, the glycine index points to potential genetic factors that could contribute to the psychomotor retardation in NKH.


Subject(s)
Benzoates/therapeutic use , Benzoic Acid/therapeutic use , Glycine/analysis , Hyperglycinemia, Nonketotic/diet therapy , Hyperglycinemia, Nonketotic/drug therapy , Adolescent , Age Factors , Age of Onset , Amino Acid Oxidoreductases , Anti-Infective Agents/therapeutic use , Carrier Proteins , Child , Child, Preschool , Diet , Female , Glycine/chemistry , Glycine/metabolism , Humans , Infant , Infant, Newborn , Male , Models, Biological , Motor Skills Disorders/pathology , Multienzyme Complexes , Sodium Benzoate/pharmacology , Time Factors , Transferases , Treatment Outcome
3.
Neurology ; 63(10): 1847-53, 2004 Nov 23.
Article in English | MEDLINE | ID: mdl-15557500

ABSTRACT

BACKGROUND: Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an autosomal recessive disorder caused by a defect in the glycine cleavage system. NKH is classically associated with neonatal apnea, lethargy, hypotonia, and seizures, followed by severe psychomotor retardation in those who survive. METHODS: To determine the natural history of NKH, the authors mailed a 44-question survey to 170 households in the International NKH Family Network. RESULTS: Data for 65 patients (36 boys, 29 girls) were collected from 58 families. One-third of the subjects died; 8 girls died during the neonatal period, and 14 patients died thereafter (2 girls, 12 boys). Median age of death for boys was 2.6 years vs <1 month for girls (p = 0.02). Mean birth weight and length, occipitofrontal circumference, and gestation duration were normal. Two-thirds of infants were ventilated during the neonatal period; of these, 40% died. Ninety percent had confirmed seizures, 75% during the first month of life. Interestingly, three NKH patients never developed seizures. An abnormal corpus callosum and/or hydrocephalus were associated with especially poor gross motor and speech development. Of 25 patients living > or =3 years, 10 were able to walk and say/sign words; all were boys. In six families with more than one affected child, disease course and mortality were similar within each family. CONCLUSIONS: This study reveals a striking and unexpected gender difference in mortality and developmental progress. Of the two-thirds of nonketotic hyperglycinemia patients surviving the newborn period, up to 20% (mostly boys) may learn to walk and communicate by saying or signing words.


Subject(s)
Hyperglycinemia, Nonketotic/epidemiology , Psychomotor Disorders/etiology , Adolescent , Age of Onset , Agenesis of Corpus Callosum , Anticonvulsants/therapeutic use , Apnea/etiology , Apnea/therapy , Child , Child, Preschool , Disease Progression , Female , Glycine/blood , Glycine/cerebrospinal fluid , Health Surveys , Humans , Hydrocephalus/epidemiology , Hydrocephalus/etiology , Hyperglycinemia, Nonketotic/complications , Hyperglycinemia, Nonketotic/metabolism , Hyperglycinemia, Nonketotic/mortality , Infant , Infant, Newborn , Male , Myoclonic Epilepsy, Juvenile/drug therapy , Myoclonic Epilepsy, Juvenile/epidemiology , Myoclonic Epilepsy, Juvenile/etiology , Nystagmus, Pathologic/epidemiology , Nystagmus, Pathologic/etiology , Pregnancy , Pregnancy Complications/epidemiology , Psychomotor Disorders/epidemiology , Registries , Respiration, Artificial , Retrospective Studies , Seizures/drug therapy , Seizures/epidemiology , Seizures/etiology , Sex Factors , Surveys and Questionnaires , Survival Analysis
4.
J Inherit Metab Dis ; 26(6): 611-2, 2003.
Article in English | MEDLINE | ID: mdl-14605508

ABSTRACT

We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects. The loss of dopaminergic neurons in this condition may make these patients more vulnerable to this severe adverse effect.


Subject(s)
Antipsychotic Agents/adverse effects , Neuroleptic Malignant Syndrome/complications , Neuronal Ceroid-Lipofuscinoses/complications , Risperidone/adverse effects , Adult , Antipsychotic Agents/therapeutic use , Creatine Kinase/blood , Dopamine/physiology , Female , Fever/complications , Hallucinations/drug therapy , Humans , Intellectual Disability , Neuronal Ceroid-Lipofuscinoses/psychology , Risperidone/therapeutic use
5.
Neurology ; 60(10): 1679-81, 2003 May 27.
Article in English | MEDLINE | ID: mdl-12771265

ABSTRACT

The authors report 1-year prospective data on eight patients with Friedreich ataxia. Idebenone did not halt the progression of ataxia. At the end of therapy, cardiac ultrasound demonstrated significant reduction of cardiac hypertrophy in six of eight patients. Cardiac strain and strain rate imaging showed that the reduction of hypertrophy is preceded by an early and linear improvement in cardiac function. Idebenone reduced erythrocyte protoporphyrin IX levels in five of six patients with elevated baseline levels; however, changes did not consistently relate to cardiac improvement.


Subject(s)
Benzoquinones/therapeutic use , Free Radical Scavengers/therapeutic use , Friedreich Ataxia/complications , Hypertrophy, Left Ventricular/drug therapy , Adolescent , Adult , Benzoquinones/pharmacology , Cardiomyopathy, Hypertrophic/drug therapy , Cardiomyopathy, Hypertrophic/etiology , Cardiomyopathy, Hypertrophic/physiopathology , Child , Erythrocytes/chemistry , Female , Free Radical Scavengers/pharmacology , Free Radicals , Friedreich Ataxia/blood , Friedreich Ataxia/genetics , Friedreich Ataxia/physiopathology , Humans , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/physiopathology , Iron-Binding Proteins/genetics , Iron-Binding Proteins/physiology , Male , Mitochondria/metabolism , Oxidative Stress , Prospective Studies , Protoporphyrins/blood , Stroke Volume , Ubiquinone/analogs & derivatives , Frataxin
6.
Bull Soc Belge Ophtalmol ; (286): 19-24, 2002.
Article in English | MEDLINE | ID: mdl-12564313

ABSTRACT

Mucolipidosis III (Pseudo-Hurler Polydystrophy) is a rare autosomal recessively inherited Hurler-like disease. The ophthalmological findings in these patients include a triad of mild retinopathy, corneal clouding and hyperopic astigmatism. We present a patient with these ophthalmological characteristics.


Subject(s)
Astigmatism/etiology , Corneal Diseases/etiology , Mucolipidoses/complications , Retinal Diseases/etiology , Adolescent , Astigmatism/diagnosis , Corneal Diseases/diagnosis , Female , Humans , Retinal Diseases/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...